Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs

Duchenne muscular dystrophy remains an untreatable genetic disease that severely limits motility and life expectancy in affected children. The only animal model specifically reproducing the alterations in the dystrophin gene and the full spectrum of human pathology is the golden retriever dog model. Affected animals present a single mutation in intron 6, resulting in complete absence of the dystrophin protein, and early and severe muscle degeneration with nearly complete loss of motility and walking ability. Death usually occurs at about 1 year of age as a result of failure of respiratory muscles. Here we report that intra-arterial delivery of wild-type canine mesoangioblasts (vessel-associated stem cells) results in an extensive recovery of dystrophin expression, normal muscle morphology and function (confirmed by measurement of contraction force on single fibres). The outcome is a remarkable clinical amelioration and preservation of active motility. These data qualify mesoangioblasts as candidates for future stem cell therapy for Duchenne patients.

[1]  Giulio Cossu,et al.  Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. , 2004, The Journal of clinical investigation.

[2]  Doris M. Miller,et al.  Muscular dystrophy in a litter of golden retriever dogs , 1988, Muscle & nerve.

[3]  R. Bartlett,et al.  An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. , 1992, Genomics.

[4]  S. Tapscott,et al.  expression in Duchenne muscular dystrophy dogs Hematopoietic stem cell transplantation does not restore dystrophin , 2013 .

[5]  R. Rogers.  Cautious optimism. , 1997, Professional nurse.

[6]  J. Nalbantoglu,et al.  Gene therapy research for Duchenne and Becker muscular dystrophies. , 1997, Current opinion in neurology.

[7]  A. Emery,et al.  The muscular dystrophies , 2002, The Lancet.

[8]  Camillo Ricordi,et al.  Clinical islet transplantation: advances and immunological challenges , 2004, Nature Reviews Immunology.

[9]  K. McDonald,et al.  Skinned single fibers from normal and dystrophin‐deficient dogs incur comparable stretch‐induced force deficits , 2005, Muscle & nerve.

[10]  M. Baiocchi,et al.  The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. , 2002, Development.

[11]  L. Kunkel,et al.  Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Pavlath.  Regulation of class I MHC expression in skeletal muscle: deleterious effect of aberrant expression on myogenesis , 2002, Journal of Neuroimmunology.

[13]  Dongsheng Duan,et al.  Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy , 2002, Nature Medicine.

[14]  K. Davies,et al.  Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer , 2003, Gene Therapy.

[15]  A. Khoruts,et al.  Visualizing the generation of memory CD4 T cells in the whole body , 2001, Nature.

[16]  N. Bresolin,et al.  Cell Therapy of α-Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts , 2003, Science.

[17]  A. Emery.  Clinical and molecular studies in Duchenne muscular dystrophy. , 1989, Progress in clinical and biological research.

[18]  M. Sampaolesi,et al.  New therapies for muscular dystrophy: cautious optimism. , 2004, Trends in molecular medicine.

[19]  S. Fletcher,et al.  Use of the dog model for Duchenne muscular dystrophy in gene therapy trials , 1997, Neuromuscular Disorders.

[20]  C. Dani,et al.  Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse , 2005, The Journal of experimental medicine.

[21]  Emery Ae.  Clinical and molecular studies in Duchenne muscular dystrophy. , 1989 .

[22]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[23]  L. Zanetta,et al.  Mesoangioblasts, Vessel-Associated Multipotent Stem Cells, Repair the Infarcted Heart by Multiple Cellular Mechanisms: A Comparison With Bone Marrow Progenitors, Fibroblasts, and Endothelial Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[24]  J. Kornegay,et al.  The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy , 2003, Neuromuscular Disorders.

[25]  Johnny Huard,et al.  Identification of a novel population of muscle stem cells in mice , 2002, The Journal of cell biology.